Blockade of ROCK2 activity using Slx-2119 inhibitor drug suppressed proinflammatory cytokines in inflamed mucosa from IBD patients including TNFα blocking infliximab-unresponsive CD patients, and inhibited IBD CD4 + T cells to differentiate into Th1 and Th17 cells through downregulating phosphorylated Stat1 and Stat3, but promoted Treg cell differentiation through upregulating phosphorylated Stat5. Here, CD4 is linked to inflammatory bowel disease.